MARKET

EPRX

EPRX

Eupraxia Pharmac
NASDAQ
8.01
-0.15
-1.84%
After Hours: 8.01 0 0.00% 19:30 09/25 EDT
OPEN
8.19
PREV CLOSE
8.16
HIGH
8.30
LOW
7.86
VOLUME
1.31M
TURNOVER
--
52 WEEK HIGH
9.32
52 WEEK LOW
5.16
MARKET CAP
531.21M
P/E (TTM)
-8.5213
1D
5D
1M
3M
1Y
5Y
1D
Wedbush Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17
Benzinga · 2d ago
Wedbush bullish on Eupraxia Pharmaceuticals, initiates with an Outperform
TipRanks · 2d ago
Eupraxia Pharmaceuticals initiated with an Outperform at Wedbush
TipRanks · 2d ago
Stifel Nicolaus Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
TipRanks · 2d ago
H.C. Wainwright Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
TipRanks · 4d ago
Weekly Report: what happened at EPRX last week (0914-0918)?
Weekly Report · 5d ago
Weekly Report: what happened at EPRX last week (0907-0911)?
Weekly Report · 09/14 09:38
Eupraxia Pharmaceuticals Moves Up to Nasdaq Global Select Market and Ramps Investor Outreach
TipRanks · 09/08 12:27
More
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.

Webull offers Eupraxia Pharmaceuticals Inc stock information, including NASDAQ: EPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EPRX stock methods without spending real money on the virtual paper trading platform.